Cheng Daye, Liang Bin, Li Yunhui
Department of Transfusion, The First Hospital of China Medical University, North Nanjing Street, No. 155, Shenyang, People's Republic of China,
Med Oncol. 2014 Oct;31(10):210. doi: 10.1007/s12032-014-0210-6. Epub 2014 Sep 2.
Emerging evidence demonstrated that hepatitis B virus X-interacting protein (HBXIP) has broad roles in cancers. The aim of the study is to investigate the association between HBXIP expression and clinicopathological features of breast cancer patients so as to determine whether HBXIP protein may be correlated with poor prognosis in breast cancer patients. HBXIP protein expression was assessed in a well-characterized series of breast cancer (n=196) with long-term follow-up, using immunohistochemistry method. Correlation between HBXIP expression and clinicopathological factors was analyzed. The effects of several variables on survival were tested by a Cox proportional hazards regression analysis. High HBXIP expression was predominantly observed in breast cancer tissues but not the adjacent normal breast tissues. The expression of HBXIP was high in 125 (63.8%) of the 196 cancer patients and low in 71 (36.2%) of the 196 patients, respectively. High HBXIP expression was positively correlated with TNM stage (P=0.001), lymph node metastasis (P<0.001), and Ki67 expression (P=0.002). The patients with high HBXIP expression had lower 5-year overall survival (OS) and disease-free survival (DFS) rates than those with low HBXIP expression as determined using the Kaplan-Meier method (OS: P=0.006; DFS: P=0.022). In Cox regression analysis, both HBXIP expression (P=0.002 and P=0.009, respectively) and lymph node metastasis (P<0.001 and P=0.008, respectively) were associated with poor OS and DFS. Our study suggested that high HBXIP is associated with the progression of breast cancer. HBXIP could be a valuable prognostic marker as well as a potential molecular therapy target for breast cancer patients.
新出现的证据表明，乙型肝炎病毒X相互作用蛋白（HBXIP）在癌症中具有广泛作用。本研究的目的是调查HBXIP表达与乳腺癌患者临床病理特征之间的关联，以确定HBXIP蛋白是否可能与乳腺癌患者的不良预后相关。采用免疫组织化学方法，对一系列特征明确且有长期随访的196例乳腺癌患者评估HBXIP蛋白表达。分析HBXIP表达与临床病理因素之间的相关性。通过Cox比例风险回归分析测试几个变量对生存的影响。主要在乳腺癌组织中观察到高HBXIP表达，而在相邻的正常乳腺组织中未观察到。在196例癌症患者中，125例（63.8%）的HBXIP表达高，71例（36.2%）的HBXIP表达低。高HBXIP表达与TNM分期（P=0.001）、淋巴结转移（P<0.001）和Ki67表达（P=0.002）呈正相关。使用Kaplan-Meier方法确定，HBXIP表达高的患者5年总生存率（OS）和无病生存率（DFS）低于HBXIP表达低的患者（OS：P=0.006；DFS：P=0.022）。在Cox回归分析中，HBXIP表达（分别为P=0.002和P=0.009）和淋巴结转移（分别为P<0.001和P=0.008）均与不良的OS和DFS相关。我们的研究表明，高HBXIP与乳腺癌进展相关。HBXIP可能是乳腺癌患者有价值的预后标志物以及潜在的分子治疗靶点。
